Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Good call!
Megola Inc (PK)
MGON
USOTC
Add to watchlist
0.014
0.0065
(
86.67%
)
Volume
5,849,615
https://ih.advfn.com/stock-market/USOTC/megola-pk-MGON/stock-price
$IVDN Sales Surge for superior, energy saving house wrap: Innovative Designs Sales Update
PITTSBURGH, PA- (NewMediaWire) - May 30, 2024 - Innovative Designs, Inc. (OTCQB: IVDN) continues its upward sales trend into the end of May 2024. Year-to-date sales have already surpassed FYE2023 by over 33% with 5 months remaining in FYE2024. The growth is attributed to a substantial increase in the number of new retailers that are now carrying the company's Insultex House Wrap®. As new energy codes are implemented across the United States, homebuilders/contractors are using Insultex House Wrap® as a convenient R-Value continuous insulation to a wall system.
Our notable growth in sales can be attributed to Built Link Solutions (Formerly Compound Construction) based in Grand Rapids, MI. Built Link Solutions is working to become the primary source for industry professionals, innovators, and stakeholders to discover, evaluate, and adopt the latest advancements in building materials, tools and technologies. Having curated a comprehensive national distribution network, they bring pioneering solutions like Insultex House Wrap® to market, propelling the evolution of the construction industry towards a future where innovation thrives, and buildings meet the needs of tomorrow. Since coming onboard, Built Link Solutions has:
Established a comprehensive national distribution network to service customers where they are when they need it.
Grown national awareness of product benefits and specifications through their dedicated sales agents and attendance at building industry trade shows across the country.
Conducted in-person sales training and online seminars to educate sales associates on Insultex House Wrap®.
Streamlined the sales process to deliver consistent and superior level service to customers of all sizes and needs.
Implemented volume pricing models and incentive discounts to meet the needs for scale and demand.
As building codes and exterior R-Value requirements are quickly evolving across the country, Built Link Solutions has proven highly proactive in contacting prospective accounts, notifying them of the cost-effective solution that our Insultex House Wrap® provides.
Randy Kimbler, Director of Business Development for Built Link Solutions, commented, "Insultex House Wrap® is gaining traction in the market as it provides a timely and effective solution. Its cost-effectiveness, innovation, and ability to address today's building challenges are driving positive feedback nationwide."
About Innovative Designs, Inc.
Innovative Designs, Inc. manufactures the Insultex® House Wrap and Arctic Armor® Line, under the "i.d.i.gear" label featuring INSULTEX®. Patented INSULTEX® is the thinnest, lightest, and warmest insulator in the market today. For more information, please visit:
http://www.idigear.comorhttp://www.insultexhousewrap.com.
Disclaimer
Certain statements in this press release constitute "forward-looking" statements as defined by federal law. Such statements are based on assumptions, but there is no assurance that actual outcomes will not be materially different as those implied. Any such statements are made in reliance on the "Safe Harbor" protections provided under the Private Securities Reform Act of 1995 and are subject to various factors, including the risks and matters discussed in the Company's SEC filings available athttp://www.sec.gov.
CONTACT:
Innovative Designs, Inc.
Joseph Riccelli, CEO
412-799-0350
joer@idigear.com
http://www.insultexhousewrap.com
Built Link Solutions
Randy Kimbler, Dir. Business Development
616-443-3200
RandyK@Builtlinksolutions.com
News Source: Innovative Designs Inc
$AVRW News: Avenir Wellness Solutions Reports Fourth Quarter 2023 Results
New Initiatives Showing Encouraging Results
SHERMAN OAKS, CA / ACCESSWIRE / May 17, 2024 / Avenir Wellness Solutions, Inc. (OTCQB:AVRW) ("Avenir" or the "Company"), a proprietary broad platform technology and wellness company, today announced results for the fourth fiscal quarter ended December 30, 2023.
Key financial highlights for the fourth quarter included the following:
Net revenue in the fourth quarter of 2023 increased to $1.1 million from the same period in 2022 by $0.2 million, or 11.7%, and also increased sequentially from Q3 2023 by $43 thousand, or 4.4%. Overall growth was lower than expected due to the continued delay in receiving the expected remainder of the asset sale proceeds to be used for advertising and marketing to drive sales. The quarter did, however, benefit from a new relationship with leading online and beauty subscription box retailer, FabFitFun.
Gross margin increased 407 basis points year over year in the fourth quarter of 2023 due to improved working capital management offset in part by a higher proportion of sales coming from our wholesale channel of distribution with its lower margins than our higher-margin direct-to-consumer sales channel.
Gross margin for the third quarter of 2023 decreased sequentially from the second quarter of 2023 by 26 basis points due to a shift in sales channel mix with a higher proportion of wholesale sales to Amazon and FabFitFun which resulted in shipments of approximately $0.3 million.
Cost containment initiatives led to a favorable impact on SG&A expenses (excluding non-cash charges) for the fourth quarter with a decrease of $357 thousand in 2023 compared to 2022 driven by decreased spend on advertising and promotion of $325 thousand lower overhead by $32 thousand.
Net operating loss from continuing operations (excluding non-cash charges) improved by $0.9 million in 2023.
"Our products continue to maintain sales levels which is encouraging given that we have been unable to fully execute on our marketing initiatives pending receipt of the balance of the proceeds from the July 2022 asset sale. As mentioned in our third quarter earnings announcement, the proceeds from the July 2022 asset sale allow us to invest in the future of the Company, but the delay in receiving the balance of the proceeds continued to have an impact on our operating performance. We expect accelerating sales will reaffirm the improving overall trajectory of the business. Further, our margin expansion initiatives continue to deliver results with improvement from third quarter, and we continue our overall cost containment initiatives to further reduce SG&A expenses and to maximize operating leverage.
Fine tuning our Search Engine Optimization (SEO), bringing our media buying in house and achieving successful monthly campaigns like theSkimm continue to deliver for us as we execute on our strategy to build our brands," said Nancy Duitch, Avenir CEO.
Operational Highlights
Other operational highlights during the fourth quarter of 2023 included:
Our newly formulated Seratopical Revolution Cracked Heel Souffle was selected for inclusion in FatFitFun's Summer 2024 subscription box selling out an astonishing 80,000 units in under 43 minutes. Click link to view Instagram videos on our Cracked Heel Souffle.
Our DNA Complex hero product continues to perform as our subscription based grows.
Wholesale sales led by Amazon continue to grow with all the positive product reviews.
We began development of our new TikTok shop to capitalize on the evolving digital ecommerce landscape which launched in the second quarter of 2024.
For further details, please visit our website to review our most recent Form 10-K filed on May 17, 2024 at: http://www.avenirwellness.com/sec-filings/
About Avenir Wellness Solutions, Inc.
Avenir Wellness Solutions, Inc. (OTCQB:AVRW) is a broad platform technology company that develops proprietary wellness, nutraceutical, and topical delivery systems which are integrated into our wellness and beauty products and sold directly to the consumer. The technology, which is based on (15) fifteen current patents, offers a number of unique immediate- and controlled-release delivery vehicles designed to improve product efficacy, safety, and consumer experience for a wide range of active ingredients. The Company will continue down the path of creating new technologies that is part of its incubator strategy in order to monetize its intellectual property as well as expand our product lines utilizing the technology. As a vertically integrated platform company, Avenir looks to partner or license its IP technology with wellness companies worldwide. For more information visit: http://www.avenirwellness.com.
About The Sera Labs, Inc.
Sera Labs, a wholly owned subsidiary of Avenir, is a trusted leader in the health, wellness, and beauty sectors of innovative products with cutting-edge technology. Sera Labs creates high-quality products that use science-backed, proprietary formulations. More than 25 products are sold under the brand names Seratopical™, Seratopical Revolution™, SeraLabs™, and Nutri-Strips™. Sera Labs sells its products at affordable prices, making them easily accessible on a global scale. Strategically positioned in the growth market categories of beauty, health and wellness, Sera Labs products are sold direct-to-consumer (DTC) via online website orders, including a subscribe and save option, and also sold online and in-store at major national drug, grocery chains, convenience stores, and mass retailers and on Amazon.com. For more information visit: http://www.seralabshealth.com and follow Sera Labs on Facebook, Instagram and TikTok at @seratopical as well as on X (Twitter) at @sera_labs.
Forward Looking Statement
This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, which statements are subject to considerable risks and uncertainties. Forward-looking statements include all statements other than statements of historical fact contained in this press release, including statements regarding the future growth and success of our organization. We have attempted to identify forward-looking statements by using words such as "anticipate," "believe," "could," "estimate," "expected," "intend," "may," "plan," "predict," "project," "should," "will," or "would," and similar expressions or the negative of these expressions.
Forward-looking statements represent our management's current expectations and predictions about trends affecting our business and industry and are based on information available as of the time such statements are made. Although we do not make forward-looking statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy or completeness. Forward-looking statements involve numerous known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements predicted, assumed or implied by the forward-looking statements. Some of the risks and uncertainties that may cause our actual results to materially differ from those expressed or implied by these forward-looking statements are described in the section entitled "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, as well as in our Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission.
Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. Except as required by applicable law, we expressly disclaim any intent or obligation to update any forward-looking statements, or to update the reasons actual results could differ materially from those expressed or implied by these forward-looking statements, whether to conform such statements to actual results or changes in our expectations, or as a result of the availability of new information.
CONTACTS:
Investor Relations
Hanover International Inc.
T: (760) 564-7400
E: investor@avenirwellness.com
Vancouver, BC, Canada, May 30, 2024–TheNewswire – First Tellurium Corp. (CSE:FTEL, OTC:FSTTF), reports it has reached a Memorandum of Understanding ("MOU") with Washington, DC-basedRESOLVE, Inc., a global non-governmental organization (NGO) focused on people and planet solutions, to secure up to approximately US$29 million (CDN$39.5 million) in funding for manufacturing and marketing as well as acquisition of high-purity tellurium, antimony and other critical metals for First Tellurium’s PyroDelta thermoelectric device (reported previously onMay 22,March 21andMarch 13).
"RESOLVE’s mission is to forge sustainable solutions to critical social, health, and environmental challenges by creating innovative partnerships," said First Tellurium’s President and CEO Tyrone Docherty. "This new venture aligns perfectly with that mission."
RESOLVE andPyroDelta Inc., in which First Tellurium currently holds a 75% interest, have formed a partnership called Tellurium Electric to bring the thermoelectric device to market. Under the MOU, RESOLVE will provide governance, administrative, and fundraising support through RESOLVE Enterprises, the organization’s incubator for start-up social enterprises, as well asRegeneration Inc., which re-mines and restores old mine tailings to extract minerals critical for the energy transition and the circular economy. Regeneration is backed by Rio Tinto, Apple, Caterpillar and other partners. A number of Regeneration’s first projects are expected to produce tellurium from copper tailings or as byproduct, which would be used for manufacturing of the PyroDelta device. Additional critical metals would be obtained on the open market.
"This is a huge step forward for us in developing new tellurium-based technologies," said Docherty. RESOLVE is a highly respected NGO, and they provide us with an established and powerful network of relevant policy, political and funding connections, including the US Government, world-leading mining companies and green investors, to help realize the potential of the PyroDelta device."
Manufacturing, marketing and sales of the device have been planned in three stages and funding segments over three years, the first of which is expected to launch near-term with an expected budget of US$1.05 million across approximately 18 months. Phases 2 and 3 are budgeted at US$3.0 million and US$15-25 million respectively.
"I believe the incubation and growth of Tellurium Electric is in the best hands possible," said Docherty. "RESOLVE and its associated partners have the skills, knowledge and networks we’ve been looking for. We will essentially be silent partners, letting RESOLVE do what they do best while we develop our own mineral projects."
Docherty added, "I want to acknowledge the generous support from our Strategic Partner Don Freschi and Fenix Advanced Materials of Trail BC, who donated several kilograms of high-purity tellurium and bismuth to launch the project."
$CCTG News: CCSC Technology International Holdings Limited Announces Plan for New Supply Chain Management Center in Central Europe
Thu, May 16, 2024, 8:00 AM EDT
In this article: $CCTG -CCSC Technology International Holdings Limited
Hong Kong, May 16, 2024 (GLOBE NEWSWIRE) -- CCSC Technology International Holdings Limited (the “Company” or “CCSC”) (Nasdaq: CCTG), a Hong Kong-based company that engages in the sale, design and manufacturing of interconnect products, including connectors, cables and wire harnesses, today announced that the Company plans to commence construction of a new Europe supply chain management center (the “Center”) located in Municipality of Merosina, Republic of Serbia (“Serbia”), in August 2024. The 50,000-square-meter facility will be CCSC’s first supply chain center project and is scheduled for completion in 2025. Once completed, it will serve as the headquarters of the Company's supply chain operations in Europe.
To further optimize production efficiency and boost synergy, in February 2024, CCSC formed a new subsidiary, CCSC Technology Doo Beograd, in Belgrade, Serbia. This subsidiary will be responsible for the operations of our new Europe supply chain management. The Company plans to adopt modern automation solutions and three-dimensional storage technology to optimize the use of the storage space, and leverage the latest digital technologies to build a smart supply chain management platform at the Center. The facility will serve as a key integrated supply chain transit hub, supporting the Company's operations across Europe.
This project is fully supported by the Merosina government, with a signed memorandum of understanding marking the collaboration between CCSC Technology Doo Beograd and the Municipality of Merosina. The total investment for the Center is estimated at US$6 million.
Mr. Kung Lok Chiu, Chief Executive Officer and Director of the Company, commented, "As part of our on-going strategic plan, we will continue to widen our strategic moat by investing in supply chain infrastructure to further enhance the agility and resiliency of our business. We believe our new Center will better support our business by driving long-term growth. This initiative is also crucial in our endeavors to become a leader in the interconnect products market. We are committed to adopting the most advanced technologies, developing replicable and scalable solutions, and fostering innovative ideas and products."
About CCSC Technology International Holdings Limited
CCSC Technology International Holdings Limited, is a Hong Kong-based company that engages in the sale, design and manufacturing of interconnect products. The Company specializes in customized interconnect products, including connectors, cables and wire harnesses that are used for a range of applications in a diversified set of industries, including industrial, automotive, robotics, medical equipment, computer, network and telecommunication, and consumer products. The Company produces both OEM (“original equipment manufacturer”) and ODM (“original design manufacture”) interconnect products for manufacturing companies that produce end products, as well as electronic manufacturing services (“EMS”) companies that procure and assemble products on behalf of such manufacturing companies. The Company has a diversified global customer base located in more than 25 countries throughout Asia, Europe and the Americas. For more information, please visit the Company’s website: http://ir.ccsc-interconnect.com.
Forward-Looking Statements
Certain statements in this announcement are forward-looking statements, including, but not limited to, the Company's proposed Offering. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that may affect its financial condition, results of operations, business strategy and financial needs. Investors can find many (but not all) of these statements by the use of words such as “may,” “will,” “could,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “propose,” “potential,” “continue”, or other similar expressions in this press release. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and other filings with the U.S. Securities and Exchange Commission.
For more information, please contact:
CCSC Technology International Holdings Limited
Investor Relations Department
Email: ir@ccsc-interconnect.com
Ascent Investor Relations LLC
Tina Xiao
Phone: +1-646-932-7242
Email: investors@ascent-ir.com
Vancouver, BC, Canada –TheNewswire -May 6, 2024– First Tellurium Corp. (CSE:FTEL, OTC:FSTTF), reports that the Company’s President and CEO Tyrone Docherty spoke to an enthusiastic audience at the Energy Transition Metals Summit in Washington DC on April 30th. The presentation focused on First Tellurium’s opportunities in critical metals mining as well as tellurium technologies related to solid-state lithium-tellurium batteries, solar energy and next-generation thermoelectric devices.
"This may have been the most important conference we’ve ever attended," said Docherty. "While our information about the Deer Horn and Klondike tellurium properties was well-received, the lithium-tellurium battery and tellurium-based thermoelectric device led to conversations with both the U.S. Department of Energy and Department of Defense. The U.S. is on a mission to develop domestic sources of critical metals and related technologies, and our story generated strong interest with representatives from both departments. We look forward to taking these discussions further."
http://firsttellurium.com/
IGPK... up about 45%. When the filings get issued its multiple dimes easy. --- Nevada Secretary of State: Name change
Name :JFH DIGITAL E-COMMERCE CORP.
Entity Type :Domestic Corporation (78)Jurisdiction :Nevada
Formation Date in Jurisdiction :
Annual Report Due Date :12/31/2024
$CBIA We’re working with a global leader to supply AI into our vending machines. This will help build our trio of acquisitions coming soon. https://twitter.com/BlueHeavenCafe/status/1786074952782782691
$CBDW announces what it believes is a monumental milestone in the realm of investor relations as it unveils its groundbreaking IR Chat solution tailored specifically for public companies and investors. https://finance.yahoo.com/news/1606-corp-unveils-ai-vertical-130000881.html
$AVRW: High prospects to deliver a record sales growth year in 2024 with the company's Seratopical brand skin care products used and endorsed by Nicole Kidman. Lots of details in the latest official company news below.
Avenir Wellness Solutions Issues 2024 Marketing Growth Plans to Shareholders for Seratopical Revolution Skin Care Line with Support from Nicole Kidman and Facial Plastic Surgeon Dr. Michael Persky
New TikTok Shop Ready for Launch to Help Grow Brand Awareness and Product Sales
News Link:
https://finance.yahoo.com/news/avenir-wellness-solutions-issues-2024-140000098.html
IGPK....check out >>>>>>> merge with a billion in Revs just about completed.. HUGE MOVE-- Last day for the cheapies...
TheStockGuru
@Austria_9999
$IGPK : JFHE
Phase - 1 second part will be fill soon. EXPECTING otc 2023 annual and first quarter 2024 report will upload in disclosure, Attorney letter will updated, Business description and insiders name Changes and yield sign will remove Today end of the day or Tomorrow!!!!!
12:17 PM · Apr 23, 2024
876 Views
$IVDN News on Rising Sales of Superior Insulation Product: Innovative Designs Vendor Growth
PITTSBURGH, PA, April 10, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Innovative Designs, Inc. (OTCQB: IVDN) continues to gain market share through its growing vendor base. Since the beginning of this fiscal year (November 1, 2023), Innovative Designs has added over 30 new accounts that have purchased its Insultex House Wrap®. This has resulted in a comp sales increase of 318% as compared to the same time period last year (November 2022 – April 2023). With 7 months remaining in FY2024, sales for the first 5 months are approaching 88% of last year's total.
Randy Kimbler, a National Distributor of Insultex, commented, “The introduction of Insultex® House Wrap to several major building supply companies has been very well-received. The product is being placed in the retail locations of these organizations, as well as many local building supply companies. The R-6 insulation value provided by this very thin product has proven to be an affordable solution for builders facing economic challenges in states where energy codes require R-5 Continuous insulation for new construction.”
About Innovative Designs, Inc.
Innovative Designs, Inc. manufactures the Insultex® House Wrap and Arctic Armor® Line, under the "i.d.i.gear" label featuring INSULTEX®. Patented INSULTEX® is the thinnest, lightest and warmest insulator in the market today. For more information, please visit http://www.idigear.com or http://www.insultexhousewrap.com.
Disclaimer
Certain statements in this press release constitute "forward-looking" statements as defined by federal law. Such statements are based on assumptions, but there is no assurance that actual outcomes will not be materially different as those implied. Any such statements are made in reliance on the "Safe Harbor" protections provided under the Private Securities Reform Act of 1995 and are subject to various factors, including the risks and matters discussed in the Company's SEC filings available at http://www.sec.gov.
CONTACT:
Innovative Designs, Inc.
Joseph Riccelli, CEO
412-799-0350
joer@idigear.com
Website: http://www.insultexhousewrap.com
Link: https://finance.yahoo.com/news/innovative-designs-vendor-growth-173800119.html
$RONN NEWS IS OUT!
RONN, Inc. Agrees to Work with H2H to Integrate Their Patented Products into Ronn Inc. Global Projects$RONNhttps://t.co/6qyICbImPu pic.twitter.com/xkfKf12lNM
— RONN inc (Formerly $LPHM) (@leepharma) April 16, 2024
$TREIF cse: $TRUE Treatment AI is quickly becoming the best assistant a doctor or nurse could ever ask for https://www.reddit.com/r/stockstobuytoday/comments/1btaegp/treif_cse_true_treatment_ai_is_quickly_becoming/
$EFSH looks primed $90m in revenues FY 2023 with spinoff/dividend in play. Tiny float 5.9m https://mailchi.mp/broadstreetalerts/efsh-breakout-alert-95653?e=
$NRXP News: NRx Pharmaceuticals (Nasdaq:NRXP) Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Four potential near-term milestones, including data from two clinical trials, an NDA filing and an upcoming share dividend
-- 50% reduction in corporate overhead and 25% reduction in overall net loss in 2023, compared to 2024 with $0.20 per share improvement in negative earnings. Additions to working capital of $8 million in Q1 2024.
-- Company forecasts first commercial revenue in 2024 from sales of ketamine and related technologies. Company received advance of first milestone payments in 2024 for ongoing development of NRX-101 from Alvogen and Lotus Pharmaceuticals, Inc. (1975.TW)
-- Company announces new partnership around the first drug to potentially modify the underlying cause of schizophrenia
-- Data lock this week and top-line data expected this month, after completed enrollment of the Phase 2b/3 trial of NRX-101 in Treatment Resistant Bipolar Depression (TRBD); trial demonstrated 94% rater concordance, far in excess of industry norms and exceeded industry norms in medication compliance
-- Two new Investigational New Drug applications (INDs) accepted by the US Food and Drug Administration (FDA) for NRX-101 in Chronic Pain and Complicated UTI.
-- Data lock expected this week in 200-person DOD-funded trial of D-cycloserine (DCS), the key component of NRX-101, to treat chronic pain, conducted by Northwestern University
-- Grant of Qualified Infectious Disease Product (QIDP), Fast Track and Priority Review designations for NRX-101 in the treatment of Complicated Urinary Tract Infection (cUTI); Publication last week of QIDP-qualifying data in a peer-reviewed journal. NRx is reviewing partnership options
-- Established HOPE Therapeutics to develop and launch IV Ketamine together with related technologies with FDA New Drug Application to be submitted this year. In advance of FDA approval, HOPE is partnered with national 503b and 503a pharmacies to address the ketamine shortage declared by FDA. HOPE is planned to be spun out as a separate company to be owned by NRx, current NRx shareholders via a tax-free dividend, and new investors; Term Sheets received from prospective anchor investors for $60 million of new investment, once publicly listed
-- HOPE is presenting data from four randomized, prospective trials demonstrating safety and efficacy in 800 patients of IV Ketamine in treating severe and suicidal depression as the clinical basis for New Drug Application (NDA) for HTX-100 (IV Ketamine); expecting stability and CMC data sufficient for NDA filing by June 2024.
-- Added over $8 million in working capital, including an advance of a $5.1 million milestone payment from partners Alvogen, Inc. and Lotus Pharmaceuticals
-- Elected nationally recognized attorney in highly regulated industries, and healthcare specialist, Janet Rehnquist, Esq., to the Company's Board of Directors
-- Management has taken actions to address NASDAQ listing compliance and naked shorting of NRx securities
-- Management to host a conference call, April 1, 2024, at 8:30 AM ET
RADNOR, Pa., April 1, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced its financial results for the quarter and year ended December 31, 2023 and provided a business update.
"2023 was a pivotal year for NRx in which we advanced from a single clinical trial in a single indication to a dramatically streamline its operations with a 50% reduction in overhead costs, a 25% reduction in overall costs, and a $0.20 per share improvement in negative earnings, while completing our clinical trial objectives. We expect data from two key trials this month and predict our first commercial revenue by the end of 2024. Over the past year the Company has navigated the most challenging business environment in the history of the biotechnology industry. Despite unprecedented headwinds, we negotiated a critical commercial partnership for our lead compound in bipolar depression, while retaining rights to the far larger indications of chronic pain and PTSD," said Stephen Willard, J.D., Chief Executive Officer and Director of NRx Pharmaceuticals. "We augmented our intellectual property portfolio to include the use of our lead compound in chronic pain and anticipate results of a 200-person efficacy trial that could open a multibillion dollar opportunity in this therapeutic area. We have acquired sufficient data on safety and efficacy of ketamine to support a New Drug Application for IV ketamine in acute suicidality. We established the foundation of a specialty pharmaceutical business around ketamine that we expect to yield positive cash flow by the end of 2024. Finally, we received unanticipated data supporting the use of our lead compound to treat complicated Urinary Tract Infection and Pyelonephritis, a condition that affects 3 million Americans and results in more than 15,000 deaths annually. We believe that NRx is poised for substantial growth in 2024 and look forward sharing further results in our conference call."
Fourth Quarter Clinical, Regulatory and Corporate Highlights
Development of NRX-101 for Treatment-Resistant Suicidal Bipolar Depression
The Company has announced today that it expects data lock this week and release of top line data this month in its Phase 2b/3 trial of NRX-101 in Suicidal Bipolar Depression. In 2023, the Company published results of a phase 2 trial demonstrating that oral NRX-101 extends the effect of IV ketamine in reducing both suicidality and depression in patients presenting to the hospital. This trial is designed to determine whether oral NRX-101 can reduce depression and suicidality in outpatients, which would be a massive broadening of the potential market for the drug. This potential expansion was guided by the Company's January 2023 meeting with the FDA in which NRx was advised to seek approval for NRX-101 as a drug for bipolar depression as a chronic, intermittent disease, a far broader indication.
With the completion of data collection, an unprecedented data integrity standard (94% agreement between site raters and central raters) has been achieved across the completed cohort of patients.
In 2023, the Company completed manufacture and Chemical Manufacturing Controls for NRX-101. This initiative is expected to yield stability data sufficient to support a shelf life in excess of two years at time of potential drug launch (should the clinical trials be successful). The completion of this manufacturing milestone allowed the Company to decrease its ongoing expenditure associated with manufacturing and development of chemical manufacturing controls.
During Q4 and in early 2024, the Company has continued to solidify its working relationship with Alvogen and Lotus, and begun working in unison to plan the final development and commercialization of NRX-101. These partners recently advanced $5 million of the first milestone to the Company. As previously announced, a successful readout from this trial and FDA interaction will trigger an additional $4 million milestone payment together with transfer of future development costs to our partner. The partnership provides for potential milestones of $329 million and a royalty reaching 15% on Net Sales.
NRX-101 for Treatment of Chronic Pain:
The Company has previously detailed the scientific basis for treatment of chronic pain with DCS as outlined in a 2016 scientific paper published by Schnitzer, et. al. and in the White Paper posted by the Company's Scientific Leadership (Sappko, et. al.). In 2023, the Company licensed US Patent 8,653,120 for the use of DCS in chronic pain and filed a now-accepted Investigational New Drug (IND) application with the FDA to initiate commercial drug development of NRX-101 in chronic pain.
Chronic pain affects more than 50 million American adults, compared to the approximately 3 million who report thoughts of suicide on an annual basis. There has been no new non-opioid class of drugs to treat nociceptive pain in the past two decades and NRX-101 has the potential to be the first N-methyl-D-aspartate (NMDA)-antagonist drug to seek approval for this indication. Today, ketamine is used off label to treat nociceptive pain, despite its clear limitations (addiction, neurotoxicity, hallucination, and the need for IV administration.)
The Company is advised that data lock will occur this week in a 200-person randomized prospective trial funded by the US DOD (NCT 03535688) in which patients with chronic pain were randomly assigned to DCS 400mg/day vs. placebo. Top line results will follow. Should these results support efficacy of DCS in the treatment of chronic low back pain, they are expected to provide a Breakthrough Therapy path towards treatment of chronic pain with DCS and DCS-containing medicines.
Spin out of HOPE Therapeutics and progress towards an NDA for NRX-100 (ketamine) in the treatment of suicidal depression.
When NRx met with the FDA in January 2023, the agency strongly encouraged the Company to develop NRX-100 (IV Ketamine) as a labeled drug, rather than rely on prior stabilization of suicidality and depression achieved via the common clinical practice of infusing generic ketamine compounded in licensed pharmacies. Shortly thereafter, the FDA issued the first of two advisory letters warning physicians against using compounded forms of ketamine and began a program of rigorous inspections of such pharmacies. Although there was once an expectation that intranasal administration of ketamine would be effective in treating suicidality, the attempts to demonstrate the clinical efficacy of nasal racemic ketamine for acute suicidality have not succeeded.
Accordingly, in Q3 the Company finalized a scientific collaboration with Prof. Marion Leboyer of Paris, France and Prof. Mocrane Abbar of Lyon, France in order to incorporate the results of a 156-person inpatient trial of intravenous ketamine vs. placebo for the stabilization of patients admitted for acute suicidality (the KETIS trial). The findings of the trial demonstrate a statistically significant reduction in both suicidality (the primary endpoint) and depression (the secondary endpoint) among patients treated with intravenous ketamine compared to those treated with placebo. (Link)
In the fourth quarter, the company similarly licensed data from Columbia University. In this trial, Dr. Michael Grunebaum and colleagues demonstrated a rapid and statistically significant reduction in Suicidal Ideation (SSI) at day 1 (p=0.0003) and in depression (P=0.0234), as measured by the Profile of Mood States (POMS) among patients randomized to IV Ketamine compared to those randomized to midazolam. This trial was published in the American Journal of Psychiatry https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5880701/.
The patient-level deidentified data from both studies have now been received by the Company and are being assembled in the electronic format required by the FDA. The Company believes that these randomized, blinded prospective trials encompassing nearly 240 participants, when submitted for review at a patient level could be sufficient to demonstrate preliminary safety and efficacy of intravenous ketamine in acutely suicidal patients. Data are expected to be transmitted to FDA by the end of 2Q23.
Submission of an NDA for the use of IV Ketamine is dependent upon submission of a manufacturing file documenting the manufacture of a presentation of ketamine suitable for single-patient use in the treatment of suicidal depression. In November 2023, the Company initiated manufacture of ketamine together with Nephron Pharmaceuticals, Inc. (West Columbia, SC) to develop a single patient presentation of ketamine. This formulation is expected to overcome some of the formulation deficiencies of existing forms of ketamine (developed for anesthesia) and is expected to have diversion-resistant and tamper-resistant features.
On March 30, 2024, the Company booked first commercial delivery of ketamine manufactured to 503b pharmacy standards from Nephron. HOPE will be distributing this presentation to qualified ketamine clinics in coordination with Nephron under Nephron's 503b pharmacy license in light of the current FDA-declared drug shortage of ketamine, starting this month (April 2024).
Treatment of Urinary Tract Infection (UTI) and Urosepsis:
Although treatment of UTI is quite different from use of NRX-101 to treat Central Nervous System disorders, D-cycloserine was originally developed as an antibiotic because of its role in disrupting the cell wall of certain pathogens. This is true of a number of drugs used in psychiatry today. D-cycloserine fell out of favor as an antibiotic in the 1970s because of the CNS effects caused by its NMDA-blocking properties and because of the widespread availability of effective first and second-generation antibiotics.
During Q3 2023, NRx tested NRX-101 and its components against resistant pathogens that appear on the Congressionally-mandated Qualified Infectious Disease Product (QIDP) list and proved in vitro effectiveness against antibiotic-resistant E. coli, Pseudomonas, and Acinetobacter. Accordingly, NRx was granted QIDP designation, Fast Track Designation, and Priority Review by the US FDA.
In recent years, increased antibiotic resistance to common pathogens that cause urinary tract infections and urosepsis (i.e., sepsis originating in the urinary tract) has resulted in a marked increase in cUTI, hospitalization, and death from urosepsis. The US Center for Disease Control and Prevention reports that more than 1.7 million Americans contract sepsis each year, of whom at least 350,000 die during their hospitalization or are discharged to hospice (CDC Sepsis Ref.). There are approximately 3 million patients per year who contract cUTI in the US annually (Lodise, et. al.). Additionally, should NRX-101 succeed in clinical trials, the Company will consider developing a follow-on product that is anticipated to achieve another 20 years of patent exclusivity.
Qualification for QIDP affords a sponsor five years of additional market exclusivity from FDA, regardless of patent status.
The Company does not anticipate funding this initiative with core NRx assets and is exploring structures for partnership opportunities. Should the Company or its partners succeed in serving 10% of the cUTI market, the Company believes that the revenue from NRX-101 has the potential to hundreds of million annually, based on 3 million cases per year (Lodise, et. al.) in the US and potential pricing of over $3,500/course of therapy.
Cash runway and financing
The Company continues to believe cash on hand is sufficient to fund operations through potential delivery of the upcoming milestones described herein.
Financial Results for the Quarter and Year Ended December 31, 2023
For the three months ended December 31, 2023, we at NRx Pharmaceuticals reduced our net loss from $10.2 million in the final quarter of 2022 to $4.3 million in 2023, representing nearly a 60% improvement year over year. For that same period, we reduced research and development expenses from $4.5 million in 2022 to $2.5 million in 2023, while substantially improving and finalizing our clinical trial enrollment. The $2.0 million decrease is related primarily to a decrease of $1.1 million in clinical trial expenses, $0.6 million in stock-based compensation, and $0.2 million in consulting and personnel wage costs. Also in that 3 month period we recorded a 67% reduction in general and administrative expenses, from $5.4 million in 2022 to $1.8 million in 2023. The decrease of $3.6 million is related primarily to a decrease of $1.3 million in insurance expenses, $1.3 million in stock-based compensation, $0.5 million in employee expenses, $0.2 million in legal and professional consulting fees, and $0.2 million in franchise tax expenses.
For the year ended December 31, 2023, NRx Pharmaceuticals reduced its net loss to $30.2 million compared to $39.8 million in the prior year. These efficiencies represent an improvement in net loss of nearly $10.0 million year over and a 20 cent, or 34%, improvement in net loss per share year over year. Over that annual period we recorded $13.4 million of research and development expenses compared to $17.0 million for the same period in 2022 representing a 21% decrease year over year. The decrease of $3.6 is related primarily to a decrease of $2.1 million in clinical trial and development expenses, $0.9 million related to fees paid to regulatory and process development consultants, $0.8 million in stock-based compensation while offset by a $0.2 million increase in patent costs as our patent portfolio has expanded.
Please note that the improvement in G&A expenses is even larger than the improvement in other areas. We decreased G&A by $13.1 million, from $27.3 million in 2022 to $14.2 million in 2023, nearly a 50% decrease year over year.
As of December 31, 2023, we had $4.6 million in cash and cash equivalents. Over the first three months of 2024 we improved our access to working capital by $8 million total, representing $2.9 million from equity sales and $5.1 million from the Alvogen milestone advance, while reducing our corporate indebtedness by 50% as shown in our financial statements.
We continue to implement operational efficiencies to extend runway and focus on our path to generating revenue. We believe that the near-term delivery of clinical trial data and the planned the launch of HOPE Therapeutics will be defining events in the second quarter of 2024.
Conference Call and Webcast Details
A live webcast of the conference call will be available on the Company's website at 8:30 a.m. ET today, at https://ir.nrxpharma.com/events. An archive of the webcast will be available on the Company's website for 30 days. Participants that are unable to join the webcast can access the conference call via telephone by dialing domestically 1-877-704-4453 or internationally 1-201-389-0920.
About NRx Pharmaceuticals
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx has partnered with Alvogen and Lotus around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRx has recently announced plans to submit a New Drug Application for HTX-100 (IV ketamine), through Hope Therapeutics, in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
About HOPE Therapeutics, Inc.
HOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a Specialty Pharmaceutical Company, wholly-owned by NRX Pharmaceuticals focused on development and marketing of an FDA-approved form of intravenous ketamine for the treatment of acute suicidality and depression together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the proposed public offering and the timing and the use of the proceeds from the offering. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy and liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
https://c212.net/c/img/favicon.png?sn=CL76439&sd=2024-04-01 View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-nasdaqnrxp-reports-fourth-quarter-and-full-year-2023-financial-results-and-provides-business-update-302104468.html
SOURCE NRx Pharmaceuticals, Inc.
$NRXP News: NRx Pharmaceutical's (NASDAQ:NRXP) Chairman Dr. Jonathan Javitt to Present at the Ketamine 2024 Conference in Oxford, UK
RADNOR, Pa., March 25, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that Dr. Jonathan Javitt, Chairman and Chief Scientist of NRx Pharmaceuticals and co-CEO of HOPE Therapeutics, will present at the Ketamine 2024 Conference, which is planned for March 25-27, 2024, at the Blavatnik School of Government in Oxford, UK.
The Ketamine 2024 Conference assembles many of the top scientists and clinicians in the field from around the world and is a forum for top researchers and experienced and interested clinicians to learn from each other about the therapeutic use of Ketamine and related compounds for affective disorders. Dr. Javitt will present a keynote talk titled, "Ketamine: the Efficacy is Clear, Approval is Critical, and the Risks Must be Balanced." He will present an overview of the rapid and dramatic efficacy of Ketamine in the treatment of acute suicidality as well as recent science documenting the potential for neurotoxicity with long-term CNS side effects if ketamine is used without appropriate safety controls as a long-term drug.
"HOPE Therapeutics builds upon four decades of scientific discovery related to the role of the brain's NMDA receptor and the effects of ketamine and other NMDA-antagonist drugs in rapidly attenuating symptoms of depression and suicidality. It is an honor for our company to be invited to share a platform with those who have established this field of science and who may forever change the outlook and future path of patients who suffer from suicidal depression and PTSD," said Dr. Javitt.
Ketamine 2024 Conference Presentation
When: Monday, March 25th, 2024
Time: 1:40-2:00 PM GMT
Title: Ketamine: The Efficacy is Clear, Approval is Critical, and the Risks Must be Balanced
About NRx Pharmaceuticals
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx has partnered with Alvogen and Lotus around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRx has recently announced plans to submit a New Drug Application for HTX-100 (IV ketamine), through Hope Therapeutics, in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
About HOPE Therapeutics, Inc.
HOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a Specialty Pharmaceutical Company, wholly-owned by NRX Pharmaceuticals focused on development and marketing of an FDA-approved form of intravenous ketamine for the treatment of acute suicidality and depression together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the proposed public offering and the timing and the use of the proceeds from the offering. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy and liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
$TWOH, DEBT REDUCTION AND READY TO MINGLE… https://twohandsgroup.com/blog/twoh-debt-free
$TWOH, DEBT REDUCTION AND READY TO MINGLE… https://twohandsgroup.com/blog/twoh-debt-free
Mark #13 to You
TIA
FIRST TELLURIUM’S NEW THERMOELECTRIC DEVICE DEMONSTRATED AT RECENT PRESENTATION
March 13, 2024
Tyrone Docherty
With robust applications for solar power, combustion engines, greenhouses and more, the device is described as a “game changer” by industry insider.
Vancouver, BC, Canada, March 13, 2024 – First Tellurium Corp. (CSE: FTEL, OTC: FSTTF), reports that investors can view a video of the Company’s recent presentation in Vancouver, which included a demonstration of the new tellurium-based thermoelectric generator developed by First Tellurium’s 51%-owned thermoelectric-focused research and development company PyroDelta Energy (“PyroDelta”). Patents for the device have been applied for in Canada and the United States.
The generator was presented to the gathering by PyroDelta co-founder Michael Abdelmaseh, who demonstrated how the device generated power from simple changes in temperature, producing energy from the heat of human skin as well as from ice. However, the generator’s primary and unique advantages come from its robust construction, low manufacturing costs, light weight and ability to withstand temperature extremes.
“Thermoelectric devices have been around for a very long time,” said Abdelmaseh. “However, none of them are suited for long-term, commercial applications that can tolerate high heat. This device can withstand temperatures of six hundred degrees Celsius.”
“This is a Game Changer”
Don Freschi, President and CEO of Fenix Advanced Materials, an industry expert who supplies metals for other thermoelectric devices, commented to the audience, “This is a game changer. I’ve never seen anything like this.”
Freschi noted that by using ultra high-purity tellurium, the device could achieve exceptional efficiencies. “Using lower purity metals, we could charge an iPhone with a tiny device,” said Freschi. “But going to high purity (99.99999 percent) tellurium, this device could power a few households.”
“The generator uses mainly tellurium,” said First Tellurium President and CEO Tyrone Docherty. “This is why Michael contacted us. He was previously in talks with a large, European luxury car manufacturer. However, believing that reliable supplies of high-purity tellurium would be key, Abdelmaseh approached First Tellurium to partner for device manufacturing.”
Production-Ready
Abdelmaseh reported that the device is ready to enter production mode. “We are done with the research and development,” said Abdelmaseh. “We have the data that shows the efficiency, and we are ready to produce it.”
As Abdelmaseh explained, PyroDelta has applied for patents on two configurations. One increases the efficiency of solar panels. The other can replace radiators and alternators in internal combustion engines, making them far more efficient and saving fuel.
Solar Panels Far More Efficient and Deployable
For solar applications, the thermoelectric device can expand the range of locations for solar power deployment, especially for sites with low sunlight and long nights. “When solar is combined with thermoelectric, you can cut down drastically the amount of battery storage required,” said Abdelmaseh.
Automobile Alternators Could Become Obsolete
In automotive applications, the device in a pipe form requires a simple retrofit to internal combustion engines without retooling assembly lines. “If you introduce anything disruptive to an existing production line that costs, say, two hundred million dollars,” said Abdelmaseh, “it’s doomed to failure. Existing vehicles can use new thermoelectric radiators, and they will generate electricity just from the heat differential of the hot liquid going through the (thermoelectric pipe) radiator and the air cooling it from the outside.” PyroDelta is presently building a thermoelectric radiator with a 1-kilowatt capacity for vehicle retrofit.
Added Abdelmaseh, “This can make your alternator obsolete. You can use the energy that’s coming out of your radiator to power all your onboard accessories—your AC, your radio, everything. This will raise the efficiency of your vehicle.”
Making Combustion Engines Significantly More Efficient
Abdelmaseh noted that today’s combustion engines generate peak efficiency of about 30-35 percent from a gallon of gas. Replacing the radiator with the thermoelectric pipe device could theoretically add an additional 12 percent in efficiency. Conservatively, Abdelmaseh estimated the added energy would total at least six-to-eight percent.
According to the U.S. Energy Administration (EIA), Americans used about 134 billion gallons of gas in 2022. An eight-percent savings would amount to over 10 billion gallons per year.
Greenhouse, Commercial Properties and Industrial Waste
Abdelmaseh also identified greenhouses, commercial properties, industrial waste and manufacturing plants as potential markets for the thermoelectric device. “Any facility with waste heat can generate electricity and lower power costs,” he said, adding that the robust construction of the device makes it ideal for harsh environments with high extremes of heat and/or cold. “The more it can withstand extremes, the more efficient it becomes,” said Abdelmaseh.
PyroDelta estimates that deploying the device in greenhouses could provide energy savings of 30 percent.
Extending Drone Battery Life
Due to the device’s small size and low weight, another large potential market would be powering drones. According to Abdelmaseh, the device as drone range extender, weighing only 70 grams (2.5 ounces), could extend a drone’s range from 15 minutes to an hour. The increased battery life could open up vast new markets, including defense and a wide range of commercial uses.
Docherty noted, “The small size of this device, which in this case is only about 50 millimeters by 100 millimeters (approximately two inches by four inches), combined with its light weight, makes it ideal for the drone market. However, any market that could benefit from these advantages of size, weight and power generation becomes accessible to us.”
First Tellurium will provide additional information about the device and potential markets in upcoming news releases.
About First Tellurium Corp.
First Tellurium’s unique business model is to generate revenue and value through mineral discovery, project development, project generation and cooperative access to untapped mineral regions in Indigenous territory with sustainable exploration.
Our Klondike tellurium-gold property in Colorado and polymetallic Deer Horn Project in British Columbia anchor a diversified search for metals, working in alliance with Indigenous peoples, NGOs, governments and leading metals buyers. This is the future of mineral exploration: generating revenue by exploring responsibly and leveraging diverse partnerships.
First Tellurium proudly adheres to and supports the principles and rights set out in the United Nations Declaration on the Rights of Indigenous Peoples and in particular the fundamental proposition of free, prior and informed consent. First Tellurium is listed on the Canadian Stock Exchange under the symbol “FTEL” and on the OTC under the symbol “FSTTF”. Further information about FTEL and its projects can be found on www.firsttellurium.com.
On behalf of the board of directors of First Tellurium Corp.
“Tyrone Docherty”
Tyrone Docherty
President and CEO
For further information please contact:
Tyrone Docherty
604.789.5653
tyrone@firsttellurium.com
Twitter: @TelluriumCorp
www.firsttellurium.com
SONX....GAME CHANGER.. this is the time to buy before Monday gets here. **** Sonendo, Inc... conference call for the Report Fourth Quarter and Full Year 2023 Financial Results on March 11, 2024
March 1, 2024
LAGUNA HILLS, Calif.--(BUSINESS WIRE)-- Sonendo, Inc. (“Sonendo”) (OTCQX: SONX), a leading dental technology company and developer of the GentleWave® System, today announced that it will report financial results for the fourth quarter and full year 2023 after the market close on Monday, March 11th, 2024. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results.
Investors interested in listening to the conference call may do so by dialing (833) 470-1428 for domestic callers or (404) 975-4839 for international callers, using access code: 426330. Live audio of the webcast will be available at: https://investor.sonendo.com.
$AHRO Analyst Target Prices $AHRO LOW TARGET 10.30
HIGH TARGET 10.3000 MEAN TARGET 10.3000 LOW TARGET 10.30
Wow and I thought .10 cents was great :)
Authentic Holdings Inc ($AHRO)
0.0008 -0.0001 (-11.11%) 03/01/24 [OTC US]
ANALYST RATINGS for Fri, Mar 1st, 2024Notes Alerts Watch Help
Analyst Target Prices
HIGH TARGET 10.3000 MEAN TARGET 10.3000 LOW TARGET 10.30 0052 WK HIGH 0.0020 52 WK LOW 0.0001
Average Analyst Ratings
3 MTHS AGO
Strong Buy
5.00
RATINGS VALUES: Strong Buy =5 Moderate Buy =4 Hold =3 Moderate Sell =2 Strong Sell =1
Ratings Breakdownhttps://www.barchart.com/stocks/quotes/AHRO/analyst-ratings
Bullish
BULLISH
$CBDW -- 1606 Corp's Partnership with Cannasite Sparks Rapid Revenue Growth for CBDW's AI-Driven Chatbot
$CBDW 1606 Corp CEO @ CES Making Deals!
$TWOH Two Hands Corporation Launches Sports Illustrated Line Protein Bars in Canada https://finance.yahoo.com/news/two-hands-corporation-launches-sports-155000347.html
Mr. Wing-Fai Ng, Group President, $AGBA Group Holding Limited said “The successful completion of our private placement is an accomplishment that speaks volumes about the strength and potential of our business. The infusion of new capital at this opportune moment will put us in a supreme position to capture growth that we now see coming in 2024.” https://finance.yahoo.com/news/agba-celebrates-major-milestone-successful-140000317.html
$SYNX Silynx videos are meant to inform our brave,
hardcore users on the best practices in using our
gear in the field. Our mission is to keep you safe
and connected as you do the hard work on the front
lines for the rest of us.
https://www.silynxcom.com/our-videos/
Pls let Sporty know about $AHRO
$CBDW Trifecta of Sales and Marketing Excellence at 1606 Corp! https://cbdw.ai/trifecta-of-sales-and-marketing-excellence-at-1606-corp/
ELTP - Rising otc gem of a lifetime!
https://bnnbreaking.com/finance-nav/elite-pharmaceuticals-shatters-expectations-with-67-revenue-growth-in-q3-2024
Latest Earning's CC - Feb. 15, 2024
"Last question, let’s see, company’s futures, what would Mr. Hakim say is the likelihood that Elite will uplift to NASDAQ within the next five years? What would Mr. Hakim say is the likelihood that Elite will get bought out by a large arrival within the next five years?"
"Two things I’ll say to that. One, cut that prediction in half or more than half. Five years is a very long time to do either. We are at a point where our fundamentals are solid, and we are in a growth stage, as I said earlier. We’re not flattening out at $30 million and $40 million. We skip the 40s, went to 50s. And we’ll talk in June once I have a little more data, what I expect for the future.
But definitely, the year after, we’re going to beat that. And the year after, we’re going to be that. So we’re at a growth stage. So the fundamentals are looking great, a buyout is looking great. And five years is way too long for that. So I would say either of this will happen in a couple of years." - CEO N.Hakim
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173856451
SONX... time to grab these cheapies before it gets relisted with NYSE possible next week. Was $10 a share then.
$TMGI Try one of our new Bundles! Matched products for maximum effectiveness, at a savings! http://SimplyWhim.com
Try one of our new Bundles! Matched products for maximum effectiveness, at a savings! https://t.co/hx8dws8fQM pic.twitter.com/BYN9QDR4uP
— Whim (@SimplyWhim) February 12, 2024
$SMME the SmartMetric biometric credit/debit card has an inbuilt hardware based live fingerprint detection created by SmartMetric and only available on the SmartMetric biometric credit/debit card. https://finance.yahoo.com/news/smartmetric-says-gen4-self-powered-144000504.html
$CAUD @CollectiveAud with wonderful host @MarketJane at the @Nasdaq
No better way to spend a snowy NYC morning than with this guy talking about what we are building, and how we are disrupting @CollectiveAud with our wonderful host @MarketJane at the @Nasdaq
— Peter Bordes (@PeterBordes) February 13, 2024
Thank you for being such a wonderful host Jane. $CAUD #advertising #adtech pic.twitter.com/azHrUKsCOu
CBIA Cancelling 581 Million Common shares
581,045,000 of these shares are the subject of a rescission agreement and are to be tendered for cancellation in the near future. Following such cancellation, the issued and outstanding shares of the Company’s common stock will be 2,206,681,572 shares, assuming not additional issuances are made. Once the cancellation is effected, the entry set forth below will be presented in the table of issuances/cancellations above
Page 8 and 24
https://www.otcmarkets.com/otcapi/company/financial-report/391929/content
$SRM Feature Article: Strong Consumer Market for NASDAQ Coming Off Original $5 IPO with New Toy & Souvenir Products for Top Clients: $SRM
Click here:
https://www.einpresswire.com/article/686503802/strong-consumer-market-for-nasdaq-coming-off-original-5-ipo-with-new-toy-souvenir-products-for-top-clients-srm
$CBDW $1606 Corp.'s CEO Interviewed by RedChip Small Stocks, Big Money™ Show regarding AI https://finance.yahoo.com/news/1606-corp-ceo-interviewed-redchip-133000578.html
Nitches (OTCPink: $NICH) Unveils Exciting Flavor Profiles for 2024 https://www.reddit.com/r/stockstobuytoday/comments/1ahcnrw/nitches_otcpink_nich_unveils_exciting_flavor/
$ARQ $ARBTF Argo's Oil Operations Update https://finance.yahoo.com/news/argos-oil-operations-145900720.html
NxGen Brands Inc. $NXGB Sets Date for 'Mad Scoops Anabolic Protein' Product Launch & Announces Product to Include Innovative 'Inclusions'
https://www.reddit.com/r/stockstobuytoday/comments/1ah7zn7/nxgen_brands_inc_nxgb_sets_date_for_mad_scoops/
$SRM Entertainment Showcases New Products at the 2024 Las Vegas Winter Market Gift Show
January 28th - February 1st Showroom C972, C975
JUPITER, FL, Jan. 29, 2024 (GLOBE NEWSWIRE) -- SRM Entertainment, Inc., (Nasdaq: SRM) (the “Company” or “SRM”) will introduce a new line of products at the iconic Winter Market 2024 in Las Vegas from January 28 through February 1st, featuring our new Zoo Animals assortment, Sealife assortment and custom designs.
The SRM Design Team’s creativity will be featured as we showcase our custom design capabilites and introduce our new Zoo Animals and Sealife poduct assortment lines at the Las Vegas Market Winter Show, a leading industry trade show (Showroom C972 & C975).
"The Las Vegas Market is the perfect West Coast venue to feature the creativity and experience of the SRM Team" said Rich Miller, CEO of SRM Entertainment. “We’re excited to showcase new products and design innovations that feature SRM’s imaginitive capabilities for 2024 and beyond.”
About SRM Entertainment, Inc.
SRM Entertainment, Inc. designs, develops and manufactures custom toys and souvenirs for the world's largest theme parks and entertainment venues. The Company provides exclusive custom products that are available worldwide at venues such as Walt Disney Parks and Resorts, Universal Studios, SeaWorld and other attractions. Additionally, SRM recently launched its retail product line which includes patented SMURFS Sip with Me cups.
Caution Regarding Forward-Looking Statements
Certain statements in this announcement are forward-looking statements. Investors can identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “potential,” “continue” or other similar expressions. These statements are subject to uncertainties and risks including, but not limited to, the risk factors discussed in the “Risk Factors” section of the registration statement for the Offering filed with the SEC. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company's registration statement and other filings with the SEC. Additional factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations that arise after the date hereof, except as may be required by law.
Media and Investor Relations
Info@SRMentertainment.com
(407)-230-8100
website: SRMentertainment.com
https://www.globenewswire.com/newsroom/ti?nf=OTAyNjY3NyM2MDQxNDA0IzUwMDExODAxNA==
https://ml.globenewswire.com/media/ZTQzZTQ4ZTQtN2U3NS00MTE4LWFiODUtZTRmNzg3ZjIzNWU2LTUwMDExODAxNA==/tiny/SRM-Entertainment-Inc-.png
Source: SRM Entertainment, Inc.
$CBDW 1606 Corp. has successfully developed a groundbreaking AI solution tailored to address the unique customer educational challenges faced by CBD merchants. https://finance.yahoo.com/news/1606-corp-accounts-skyrocket-december-133000797.html
Followers
|
473
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
10333
|
Created
|
06/18/16
|
Type
|
Free
|
Moderator SPORTYNORTY | |||
Assistants i_like_bb_stock Golden Cross srm4u AdamS007 $Pistol Pete$ ranger_7 |
THE WOOF OF WALL STREET
(IMPORTANT RULES AND CLARIFICATIONS)
When the concept of this board was being developed, having the benefit of being on I-HUB since June/2006, and actively trading in the markets, primarily penny, but I also traded big board stocks as well, I
wanted to create a board where traders, regardless of their respective experiences, could congregate and prosper. It was also quintessential to me, that the appointed Assistant Moderators on the board,not
only possess a strong foundation of trading acumen, but that they possess two crucial personal traits:, HONESTY and INTEGRITY. People can be taught technical analysis, how to trade on momentum, how
to avoid prolific scams etc…But if an individual, at this stage of their life does not have HONOR or INTEGRITY, then quite frankly, they should not be here.
I want everyone who reads this message to understand this one thing; We at THE WOOF OF WALL STREET are trying our best to find undervalued stocks which we ourselves, and all of our loyal followers,
can accumulate at the lowest possible price, thus making the most amount of profit. Most of the times that works, but, no one is perfect.
You see, I grew tired of watching some of the best traders on I-HUB, back in the day, utilize their skills, and their member marks to market themselves and in my humble opinion, sell their souls to these
unscrupulous penny companies by running these damn, "Awareness Campaigns, stock promos and such." In my opinion, the giving of shares in exchange for pumping scam stocks, then dumping on the
uninformed investors, trying to make some extra money to provide for their families, is not only unconscionable, but should be ILLEGAL.
When confronted with a wrong, an individual must decide whether they are going to stand idly by and allow it to continue, or even worse, assist in its execution. Not me, not ever. I believe each and every
person has a right to make a few extra bucks, and to do so, they need a fighting chance.
The aforementioned diatribe is the underlying principles by which I endeavored to pursue starting this board in the first place. Now that we have hopefully re-established those tenets, let us address some
other issues which have come up recently:
1) FEATURED PICKS - We have always maintained that the FEATURED PICK alerts should be a grand slam, and to again, be perfectly honest here, there just has not been a plethora of FP
worthy equities. A FEATURED PICK can ONLY be posted/alerted by me, so as not to add to the confusion on the board. Our FEATURED PICKS should be traded generally within a 4-9 trading
session timeframe.
2) TRADE ALERTS--Can ONLY be issued by a WOOF OF WALL STREET MODERATOR. "TRADE ALERT," is verbiage we have all agreed upon to distinguish an alert, which does not meet the
FEATURED PICK criteria, but nonetheless we feel is a good trade. A TRADE ALERT has no set timeframe, as it can, and in most cases should, be treated as a day trade, maybe even a 2 day
trade. TRADE ALERTS normally have some type of catalyst, (news event, reverse merger, financing, etc…)
3) A TECHNICAL TRADE ALERT--Also can ONLY BE ISSUED by a WOOF OF WALL STREET MODERATOR, for the same reasons articulated above. A TECHNICAL TRADE ALERT is only
different from a regular TRADE ALERT, in so far, as it is solely based upon technical analysis, (over sold, blue sky breakout, cup and handle, etc…) (TECHNICAL TRADE ALERTS may or may
not have a forward looking catalyst coming, and are merely, as stated before, being issued soley based upon technical analysis).
4) Finally, we have GENERAL STOCK TIPS/ALERTS: These can be issued by any poster on the open WOOF OF WALL STREET forum and should be traded or not traded based upon each
person's own individual assessment.
**I DO NOT FIND IT PRODUCTIVE TO BASH OTHER POSTERS' STOCK PICKS. FUTURE POSTINGS DIRECTED AT INDIVIDUALS, AND OR POSTS BASHING STOCKS WILL SUMMARILY BE
REVIEWED, AND POSSIBLY REMOVED.*** THE ONE EXCEPTION TO THIS RULE, IS WHEN THE PERSON(S)
ISSUING THE ALERT SOLICIT OPEN FORUM OPINIONS OF SAID ALERTS. ***( ask us no questions and we will tell you no lies)
We at THE WOOF OF WALL STREET DO NOT ENGAGE, (NOR WILL WE EVER), in the following activities:
FRONT LOADING
NEWS LETTERS
PAID COMPENSATION FOR PROMOTIONAL CAMPAIGNS TOUTING STOCKS (EITHER IN CASH OR FREE STOCK)
We at THE WOOF OF WALL STREET appreciate your continued support, positive feedback and most of all your loyalty. We are actively looking for our next FEATURED PICK, and will as always
provide our followers with a 24 hour warning as to when it will be publicly announced. In the interim, we will continue issuing TRADE ALERTS/TECHNICAL TRADE ALERTS and other stock tips
as discerned and warranted.
Regards,
SPORTYNORTY
ALL SMILEYS GIFER
https://www.allsmileys.com/ https://tenor.com/search/crowd-gifs https://gifer.com/en/category/Reactions
STOCK SCAN LINKS & TRADING TOOLS
More than 100 publicly traded companies https://privateequitymarkets.us/companies/gold
Nasdaq daily losers list http://www.blackberrystocks.com/stocklosers.html
Top 100 penny stock losers http://pennystocklist.com/List-of-Penny-Stocks.html?qm_page=26579
http://stockcharts.com
https://www.barchart.com/
http://www.stockhouse.com
http://www.stockfetcher.com/
http://www.stockciphering.com/index.htm
http://markets.usatoday.com/custom/usatoday-com/screener/screener.asp
Sub Penny Stocks Big Profit Potential
Sub Penny Stocks are stocks that are currently being traded at a fraction of a cent. For example, the price per share for a sub penny stock could be $0.0001 which means that this sub penny stock is trading
at 1/100th of a penny. Don’t let the low price of sub penny stocks fool you. There is still big money that can be made by trading sub penny stocks especially if that sub penny stock has a low float. Sub penny
stocks that have a low float have the tendency to move on high volume.The reason for this is that sub penny stocks allow investors to get more shares off their initial investment. A penny stock investor could
pick up one hundred thousand shares of a sub penny stock trading at $.001 for just $100 . When the volume for the stock is high you have lots of investors in demand of a sub penny stock with a limited
supply of shares which causes the price of the sub penny stock to go up steeply and in a short amount a time.
Stock Trading Tips Worth Memorizing
Trading is a constant game of learning, failing and gaining experience. The old story of Babe Ruth is an incredible lesson for all us traders. In the year that Babe Ruth hit the most home runs, he also struck
out the most! To hit home runs in trading, you will have to strike out and the more you strike out the more home runs you can hit. Here are some of my best stock trading tips to help you win more trades
more often.
Trading Volume
One of the most important indicators to look at is the volume of a stock. Volume is an indication of how active a stock is. It is also an indication of how much money is flowing in and out of that particular stock.
We ALWAYS want to FOLLOW the money. Volume is a great indication of the flow of money. Low volume stocks are "dead" and although they may be safe they won't make us money.
Buy On Weakness, Sell On Strength
One of the very first things I learned when I started online trading, but I must admit that it took me years to fully understand that this is the crux of it all. When you buy on weakness you buy a bargain. When
you sell on strength you make a profit. Simple as that. Buying on weakness means that you are buying something that is undervalued. It's like buying a $100 bill for $50. As soon as you start chasing stocks
and holding on too long you start breaking this fundamental rule.
Moving Averages
My favorite tool for analyzing any stock. In fact, I love it so much it's almost the first thing I look at. Moving averages is in my opinion one o the most accurate ways to see which direction a stock is moving.
This is one of my best stock trading tips I can give you. Look at the moving averages and look at the crossovers - this is when buy and sell signals usually appear.
Check The News
As a predominantly technical trader, I was slow at catching on to this since I hate fundamental analysis. However, this is a simple and quick way to spot changes in a particular stock price. Just take a couple
of minutes to do a search in Yahoo Finance or in your eTrade console for the latest financial news about that stock. Doing a quick search in that sector is also a good idea and be on the lookout for anything
that can significantly affect the market perception.
Let The Winners Run, Cut Your Losers Short
It almost sounds ridiculous but how often do we hold on to stocks that we "fall in love with" HOPING that it will make a comeback and run the way we hoped it would? It's simple, if a stock is not doing what
you planned for it, cut it off. On the other hand, if a stock starts running you should let it go and throw your full weight behind it.
Plan Your Trades, Trade Your Plan
It's vital to have a very clear plan on every single trade you make. You must have a definite entry price, a definite exit point and you must have stop losses in place. Trading with a plan is not just about giving
yourself some rules, but it's about discipline and being a good money manger. Thinking that you can go with the flow and play it as it comes is just plain stupid and a recipe for disaster.
INVESTING 101: TIP #1 (INVESTING IN PENNY STOCKS DD)
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=161877324
Share structure is a very important metric when evaluating whether or not to invest in a stock.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=161896594
I hope these few stock trading tips will help you out. They are really that important and something that I believe will help you a lot.
FINAL THOUGHTS:
Set a Realistic Goal- What is it that you are trying to accomplish? Do you want to earn $100 per week, per day, or per hour? How often do you want to trade? Are you able to trade during day time hours, or
will you have to place your orders after hours?
Get some training- You need to find 1-3 good strategies that fit your risk tolerance and trading style. You can pick up some good information for books on trading at your local library or book store. You can
also find some online stock trading information. The key here is to make sure that you are learning from someone who currently trades profitably with the style of trading you will like to trade.
Understand risk management- It is possible to have a 30% winners and 70% losing trades and still be profitable. The key is to learn how to cut your losses short and let your winners run. For example if
you risk $50 max loss per trade and expect to earn $75 to $125 per trade. Then if you had 3 winners (125 * 3= $375) and 7 losers (50 * 7= $350) you will still be profitable. Assuming you have low
commission cost.
Pay as little as possible in commission- Commissions can eat into your profits, select a reputable low commission broker. If you can pay less than $1 in commission to buy and sell, then for 100 shares or
more traded you only need one penny to profit. Be patient and picky- Don't rush into online trades, be very patient and picky about your trades. In other words, plan your work and work your plan. If you fail to
plan you plan to fail. However, always be willing to accept that you made a bad trade and move on, because losses will happen.
Posts Today
|
0
|
Posts (Total)
|
10333
|
Posters
|
|
Moderator
|
|
Assistants
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |